{"url_path":"/sec/cik-0001845459/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1845459/0001213900-26-060160-index.html","accession_number":"0001213900-26-060160","cik":"0001845459","ticker":null,"issuer_name":"NKGen Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1845459/0001213900-26-060160-index.html","primary_entity_key":"0001845459","primary_entity_name":"NKGen Biotech, Inc."},"word_count":224,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n10.1\n \n[Second Amendment to Secured Convertible Loan Agreement, dated May 15, 2026, by and among NKGen Biotech, Inc., NKGen Operating Biotech, Inc., and AlpineBrook Capital GP I Limited.](ea029158201ex10-1.htm)\n\n10.2\n \n[Secured\nConvertible Promissory Note (Additional Note #2), dated May 15, 2026, issued by NKGen Biotech, Inc. and NKGen Operating Biotech,\nInc. in favor of AlpineBrook Capital GP I Limited.](ea029158201ex10-2.htm)\n\n10.3*\n \n[Common\nStock Purchase Warrant, dated May 15, 2026, issued by NKGen Biotech, Inc. to AlpineBrook Capital GP I Limited.](ea029158201ex10-3.htm)\n\n10.4\n \n[Voting\nAgreement, dated May 15, 2026, by and among NKGen Biotech, Inc., AlpineBrook Capital GP I Limited, Graf Acquisition Partners IV LLC,\nNKGen Biotech Korea Co., Ltd., and Paul Song.](ea029158201ex10-4.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the\nInline XBRL document)\n\n \n\n*\nCertain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of Securities Exchange\nAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n**NKGEN BIOTECH, INC.**\n\n \n \n \n\nDate: May 21, 2026\n/s/ Paul Y. Song\n\n \nName:\nPaul Y. Song\n\n \nTitle:\nChief Executive Officer\n\n \n \n*(Principal Executive Officer)*\n\n \n\n3"}